Feliza Mirasol

1 week ago | biopharminternational.com | Feliza Mirasol

Cell harvesting is an important step in the manufacture of biologic modalities, and one area where automation technologies can play a major role. Traditionally, cell harvesting has relied heavily on centrifugation and depth filtration, both labor-intensive techniques that are prone to variability. But recent advances in automation technologies have significantly improved the efficiency, scalability, and consistency of cell harvesting to enable more streamlined bioprocessing workflows.

2 weeks ago | biopharminternational.com | Feliza Mirasol

The biopharmaceutical R&D landscape has undergone significant transformation in the past decade, as evidenced by unprecedented diversity in the industry’s pipeline composition as well as current therapeutic approaches. In today’s biopharma R&D environment, there is a critical shift from traditional primary-care focus to a more nuanced, specialty-driven landscape.

2 weeks ago | biopharminternational.com | Feliza Mirasol

Editor's note: this story was originally published on PharmTech.com. CN Bio, a provider of organ-on-a-chip (OOC) systems and solutions aimed at accelerating drug discovery and development workflows, announced on April 24, 2025, that it has entered into a strategic partnership with Pharmaron, a China-based R&D service provider for the life sciences industry, under which Pharmaron will validate CN Bio’s PhysioMimix technology across existing applications.

3 weeks ago | biopharminternational.com | Feliza Mirasol

On April 22, 2025, AnalytiChem, a German manufacturer of specialized laboratory equipment, reagents, and consumables, announced the global launch of Redipor, a ready-to-use culture media, as an AnalytiChem-branded product line. The product line builds on three well-known brands: BioTrading, Redipor by Cherwell, and NEL. Under the newly introduced Redipor line, these products are brought together into one global brand.

3 weeks ago | biopharminternational.com | Feliza Mirasol

Netherlands-based Avidicure is a new biotechnology company that has been launched from a $50 million seed financing round. Announcing the launch on April 24, 2025, the company said it aims to develop a new multifunctional antibody modality that will have broad applicability in oncology. The financing round was led by EQT Life Sciences. Other participants included Kurma Partners, BioGeneration Ventures, BOM, Curie Capital, and V-Bio Ventures.